1-3 of 3
Solly George, RN
Close
Sort by
Journal Articles

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Alireza Eghtedar, MD, Srdan Verstovsek, MD, PhD, Jorge E. Cortes, MD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Carol Bivins, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Solly George, RN, Robert Newton, PhD, Hagop Kantarjian, MD, Farhad Ravandi, MD
Journal: Blood
Blood (2010) 116 (21): 509.
https://doi.org/10.1182/blood.V116.21.509.509
Published: 2010
Journal Articles

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Solly George, Rn, Carol Bivins, Rn, Jorge Cortes-Franco, MD, William M Garrett, MBA, Robert C Newton, PhD, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 631.
https://doi.org/10.1182/blood.V114.22.631.631
Published: 2009
Journal Articles

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Francis Giles, MD, David A. Rizzieri, MD, Solly George, RN, Wendy Stock, MD, Jeannie Fontanilla, BS, Gavin S. Choy, PharmD, Gregory I. Berk, MD
Journal: Blood
Blood (2006) 108 (11): 1968.
https://doi.org/10.1182/blood.V108.11.1968.1968
Published: 2006